5-(1-tert-butyl-1H-pyrazol-4-yl)-6-isopropyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile

ID: ALA3785583

Chembl Id: CHEMBL3785583

PubChem CID: 118908379

Max Phase: Preclinical

Molecular Formula: C17H20N6O

Molecular Weight: 324.39

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CC(C)c1c(-c2cnn(C(C)(C)C)c2)[nH]c2c(C#N)cnn2c1=O

Standard InChI:  InChI=1S/C17H20N6O/c1-10(2)13-14(12-8-19-22(9-12)17(3,4)5)21-15-11(6-18)7-20-23(15)16(13)24/h7-10,21H,1-5H3

Standard InChI Key:  KRXWJZIHQRIGSJ-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA3785583

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 324.39

Molecular Weight (Monoisotopic): 324.1699

AlogP: 2.64

#Rotatable Bonds: 2

Polar Surface Area: 91.77

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 10.41

CX Basic pKa: 1.59

CX LogP: 1.87

CX LogD: 1.87

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.78

Np Likeness Score: -1.27

References

1. McAllister TE, England KS, Hopkinson RJ, Brennan PE, Kawamura A, Schofield CJ..  (2016)  Recent Progress in Histone Demethylase Inhibitors.,  59  (4): [PMID:26710088] [10.1021/acs.jmedchem.5b01758]

2. Liang J, Zhang B, Labadie S, Ortwine DF, Vinogradova M, Kiefer JR, Gehling VS, Harmange JC, Cummings R, Lai T, Liao J, Zheng X, Liu Y, Gustafson A, Van der Porten E, Mao W, Liederer BM, Deshmukh G, Classon M, Trojer P, Dragovich PS, Murray L..  (2016)  Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.,  26  (16): [PMID:27406798] [10.1016/j.bmcl.2016.06.078]

3. Zheng YC, Chang J, Wang LC, Ren HM, Pang JR, Liu HM..  (2019)  Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.,  161  [PMID:30343192] [10.1016/j.ejmech.2018.10.040]

4. Yang GJ, Wu J, Miao L, Zhu MH, Zhou QJ, Lu XJ, Lu JF, Leung CH, Ma DL, Chen J..  (2021)  Pharmacological inhibition of KDM5A for cancer treatment.,  226  [PMID:34555614] [10.1016/j.ejmech.2021.113855]

Source

Source(1):

• Scientific Literature